We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical ... read more Featured Products: More products

Download Mobile App





SNIBE Brings Latest Innovations in Immunoassay, Clinical Biochemistry and Molecular Diagnostics to Medlab Middle East 2023

By LabMedica International staff writers
Posted on 09 Feb 2023
Print article
Image: SNIBE is presenting its latest innovations in laboratory diagnostics at Medlab Middle East 2023 (Photo courtesy of SNIBE)
Image: SNIBE is presenting its latest innovations in laboratory diagnostics at Medlab Middle East 2023 (Photo courtesy of SNIBE)

SNIBE (Shenzhen, China) is bringing its latest innovations, including new members from its product lines in immunoassay, clinical biochemistry and molecular diagnostics to Medlab Middle East 2023.

At Medlab Middle East 2023, SNIBE is showcasing Biolumi CX8, the new lab booster that combines one of the fastest immunoassay system MAGLUMI X8, and the biochemical system Biossays C8, with ultra-high throughput in a very small footprint. Moreover, it can also be customized according to specific needs, supporting up to four connected instruments, and covering the requirements of different laboratories. SNIBE is also showcasing the MAGLUMI X6 flexible CLIA solution that is designed for medium/high-volume laboratories. The MAGLUMI X6 offers flexible configuration modules and features new generation hydraulic TIP pipetting technology. It has a high speed of 450 tests/hour and is suitable for 155 chemiluminescence immunoreagents.

In addition, SNIBE is highlighting the Molecision S6 automated, integrated digital PCR system that provides a full-platform solution for research/in vitro diagnostics. Molecision S6 uses a cutting-edge cartridge that provides uniform droplets and prevents contamination, maximizing operation productivity and cost efficiency. Light oil is pre-filled in the cartridge so that the droplets can be sunk under the light oil to ensure a fully enclosed condition, achieving a sensitivity of 0.002%. Its highly integrated design and optimized system make it space-saving and easy to use. Alongside the Molecision S6, SNIBE is highlighting the Molecision MP-32 and MP-96 fully-auto nucleic acid purification systems that adopt a high-performance magnetic extraction method, thereby maximizing the recovery rate and consistency of results.

Related Links:
SNIBE

Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
New
POC Single-Use IVD Test
i-STAT CHEM8+ Cartridge
New
Infection Laboratory Test Panels
Synovasure
New
Gliadin IgG Test
Gliadin IgG Test System

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more

Pathology

view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.